165 related articles for article (PubMed ID: 37212907)
1. 68Ga-PSMA PET/CT evaluation in men enrolled in prostate cancer Active Surveillance.
Pepe P; Pepe L; Tamburo M; Marletta G; Savoca F; Pennisi M; Fraggetta F
Arch Ital Urol Androl; 2023 May; 95(2):11322. PubMed ID: 37212907
[TBL] [Abstract][Full Text] [Related]
2. Could 68Ga-PSMA PET/CT Evaluation Reduce the Number of Scheduled Prostate Biopsies in Men Enrolled in Active Surveillance Protocols?
Pepe P; Roscigno M; Pepe L; Panella P; Tamburo M; Marletta G; Savoca F; Candiano G; Cosentino S; Ippolito M; Tsirgiotis A; Pennisi M
J Clin Med; 2022 Jun; 11(12):. PubMed ID: 35743547
[TBL] [Abstract][Full Text] [Related]
3. Targeted prostate biopsy: 68Ga-PSMA PET/CT vs. mpMRI in the diagnosis of prostate cancer.
Pepe P; Pepe L; Tamburo M; Marletta G; Pennisi M; Fraggetta F
Arch Ital Urol Androl; 2022 Sep; 94(3):274-277. PubMed ID: 36165469
[TBL] [Abstract][Full Text] [Related]
4. Detection Rate of
Pepe P; Pepe L; Cosentino S; Ippolito M; Pennisi M; Fraggetta F
Anticancer Res; 2022 Jun; 42(6):3011-3015. PubMed ID: 35641295
[TBL] [Abstract][Full Text] [Related]
5. Targeted Biopsy in Men High Risk for Prostate Cancer:
Pepe P; Pennisi M
Clin Genitourin Cancer; 2023 Dec; 21(6):639-642. PubMed ID: 37394379
[TBL] [Abstract][Full Text] [Related]
6. Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer.
Amin A; Blazevski A; Thompson J; Scheltema MJ; Hofman MS; Murphy D; Lawrentschuk N; Sathianathen N; Kapoor J; Woo HH; Chalasani V; Rasiah K; van Leeuwen PJ; Tang R; Cusick T; Stricker P; Emmett L
BJU Int; 2020 Apr; 125(4):515-524. PubMed ID: 31957122
[TBL] [Abstract][Full Text] [Related]
7. The use of
Yang J; Tang Y; Zhou C; Zhou M; Li J; Hu S
Prostate; 2023 Apr; 83(5):430-439. PubMed ID: 36544382
[TBL] [Abstract][Full Text] [Related]
8. Fluorine-18-labelled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography or Magnetic Resonance Imaging to Diagnose and Localise Prostate Cancer. A Prospective Single-arm Paired Comparison (PEDAL).
Wong LM; Sutherland T; Perry E; Tran V; Spelman T; Corcoran N; Lawrentschuk N; Woo H; Lenaghan D; Buchan N; Bax K; Symons J; Saeed Goolam A; Chalasani V; Hegarty J; Thomas L; Christov A; Ng M; Khanani H; Lee SF; Taubman K; Tarlinton L
Eur Urol Oncol; 2024 Jan; ():. PubMed ID: 38281891
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric MRI and
Privé BM; Israël B; Janssen MJR; van der Leest MMG; de Rooij M; van Ipenburg JA; Jonker M; Peters SMB; de Groot M; Zámecnik P; Hoepping A; Bomers JG; Gotthardt M; Sedelaar JPM; Barentsz JO; van Oort IM; Nagarajah J
Radiology; 2024 May; 311(2):e231879. PubMed ID: 38771185
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic Performance and Clinical Impact of PSMA PET/CT versus mpMRI in Patients with a High Suspicion of Prostate Cancer and Previously Negative Biopsy: A Prospective Trial (PROSPET-BX).
Lopci E; Lazzeri M; Colombo P; Casale P; Buffi NM; Saita A; Peschechera R; Hurle R; Marzo K; Leonardi L; Morenghi E; Balzarini L; Disconzi L; Guazzoni G; Chiti A; Lughezzani G
Urol Int; 2023; 107(5):433-439. PubMed ID: 36724746
[TBL] [Abstract][Full Text] [Related]
11. Detection rate for significant cancer at confirmatory biopsy in men enrolled in Active Surveillance protocol: 20 cores vs 30 cores vs MRI/TRUS fusion prostate biopsy.
Pepe P; Cimino S; Garufi A; Priolo G; Russo GI; Giardina R; Reale G; Barbera M; Panella P; Pennisi M; Morgia G
Arch Ital Urol Androl; 2016 Dec; 88(4):300-303. PubMed ID: 28073197
[TBL] [Abstract][Full Text] [Related]
12. Reproducibility and Accuracy of the PRIMARY Score on PSMA PET and of PI-RADS on Multiparametric MRI for Prostate Cancer Diagnosis Within a Real-World Database.
Emmett L; Papa N; Counter W; Calais J; Barbato F; Burger I; Eiber M; Roberts MJ; Agrawal S; Franklin A; Xue A; Rasiah K; John N; Moon D; Frydenberg M; Yaxley J; Stricker P; Wong K; Coughlin G; Gianduzzo T; Kua B; Ho B; Nguyen A; Liu V; Lee J; Hsiao E; Sutherland T; Perry E; Fendler WP; Hope TA
J Nucl Med; 2024 Jan; 65(1):94-99. PubMed ID: 38050155
[TBL] [Abstract][Full Text] [Related]
13. The PRIMARY Score: Using Intraprostatic
Emmett L; Papa N; Buteau J; Ho B; Liu V; Roberts M; Thompson J; Moon D; Sheehan-Dare G; Alghazo O; Agrawal S; Murphy D; Stricker P; Hope TA; Hofman MS
J Nucl Med; 2022 Nov; 63(11):1644-1650. PubMed ID: 35301240
[TBL] [Abstract][Full Text] [Related]
14. Combined Utility of
Kalapara AA; Ballok ZE; Ramdave S; O'Sullivan R; Ryan A; Konety B; Grummet JP; Frydenberg M
Eur Urol Oncol; 2022 Jun; 5(3):314-320. PubMed ID: 33741337
[TBL] [Abstract][Full Text] [Related]
15. The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study.
Emmett L; Buteau J; Papa N; Moon D; Thompson J; Roberts MJ; Rasiah K; Pattison DA; Yaxley J; Thomas P; Hutton AC; Agrawal S; Amin A; Blazevski A; Chalasani V; Ho B; Nguyen A; Liu V; Lee J; Sheehan-Dare G; Kooner R; Coughlin G; Chan L; Cusick T; Namdarian B; Kapoor J; Alghazo O; Woo HH; Lawrentschuk N; Murphy D; Hofman MS; Stricker P
Eur Urol; 2021 Dec; 80(6):682-689. PubMed ID: 34465492
[TBL] [Abstract][Full Text] [Related]
16. Which Prostate Biopsy in Men Enrolled in Active Surveillance? Experience in 110 Men Submitted to Scheduled Three-Years Transperineal Saturation Biopsy Combined With Fusion Targeted Cores.
Pepe P; Pepe L; Pennisi M; Fraggetta F
Clin Genitourin Cancer; 2021 Aug; 19(4):305-308. PubMed ID: 33642223
[TBL] [Abstract][Full Text] [Related]
17. Prospective Evaluation of
Lopci E; Lughezzani G; Castello A; Saita A; Colombo P; Hurle R; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Casale P; Pietro D; Bevilacqua G; Balzarini L; Buffi NM; Guazzoni G; Lazzeri M
Eur Urol Focus; 2021 Jul; 7(4):764-771. PubMed ID: 32312701
[TBL] [Abstract][Full Text] [Related]
18. Oncological Outcomes in Men With Favorable Intermediate Risk Prostate Cancer Enrolled in Active Surveillance.
Pepe P; Pepe L; Pennisi M; Fraggetta F
In Vivo; 2024; 38(3):1300-1305. PubMed ID: 38688647
[TBL] [Abstract][Full Text] [Related]
19. A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy.
Kelly BD; Ptasznik G; Roberts MJ; Doan P; Stricker P; Thompson J; Buteau J; Chen K; Alghazo O; O'Brien JS; Hofman MS; Frydenberg M; Lawrentschuk N; Lundon D; Murphy DG; Emmett L; Moon D
Eur Urol Open Sci; 2023 Jul; 53():90-97. PubMed ID: 37441340
[TBL] [Abstract][Full Text] [Related]
20. Head-to-Head Comparison of
Exterkate L; Hermsen R; Küsters-Vandevelde HVN; Prette JF; Baas DJH; Somford DM; van Basten JA
Eur Urol Oncol; 2023 Dec; 6(6):574-581. PubMed ID: 37230883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
